Who Paid My Doc
Philp Darney
Public Health & General Preventive Medicine San Francisco, CA Medical Doctor
NPI 1205880697 CMS profile 54788
1001 Potrero Ave, Rm 6D14, San Francisco, CA 94110
General payments
$12,891
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$32,765
Through program year 2021, Philp Darney of San Francisco, CA is reported in the CMS Open Payments database as having received $12,891 across 12 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $32,765 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Public Health & General Preventive Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $2,275 | 1 | |
| 2020 | General | $1,666 | 4 | |
| 2019 | General | $8,950 | 7 |
Beside peers
- Philp Darney
- Public Health & General Preventive Medicine median
- Middle half of Public Health & General Preventive Medicine
- National median
In program year 2025, general payments to Philp Darney were reported at $0. Among 185 Public Health & General Preventive Medicine profiles paid that year, the median was $99 and the middle half received between $32 and $365.
Show as a table
| Year | Philp Darney | Public Health & General Preventive Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,950 | $99 | $22–$287 | $163 |
| 2020 | $1,666 | $101 | $21–$478 | $114 |
| 2021 | $2,275 | $99 | $31–$856 | $132 |
| 2022 | $0 | $79 | $24–$340 | $149 |
| 2023 | $0 | $102 | $28–$326 | $160 |
| 2024 | $0 | $98 | $27–$291 | $164 |
| 2025 | $0 | $99 | $32–$365 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Public Health & General Preventive Medicine in California
Steven Galson
Public Health & General Preventive Medicine · Thousand Oaks, CA
Ryan Zane
Public Health & General Preventive Medicine · San Bernardino, CA
Ross Miller
Public Health & General Preventive Medicine · Beverly Hills, CA
Daniel Cosgrove
Public Health & General Preventive Medicine · Indian Wells, CA
Karen Studer
Public Health & General Preventive Medicine · Loma Linda, CA
George Rutherford
Public Health & General Preventive Medicine · San Francisco, CA
Related records
Public Health & General Preventive Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Public Health & General Preventive Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.